Neblo, glad to hear of your success! You deserve it, I am quite sure.
To elaborate a bit more on my thoughts...In the 'old' days, the most common type of lung CA was 'Squamous.' It was a fairly radiation-sensitive cell type (similar again to H & N Squamous). Some ten or so years ago, the classification of lung CA was changed into Small Cell and Non Small Cell Carcinoma, with the latter category including the 'old' Squamous as a subtype. In the meantime, the frequency of some other subtypes seemed to increase, so that now the Squamous carcinomas account for something in the vicinity of 20-30% of all lung CAs (that percentage is just a wild guess, as I did not look it up just now). The differentiation/developmental process of the cells in the upper versus lower respiratory tracts are very similar in utero, such that the squamous tumors of the H & N share an extremely similar physiology to those of the bronchi of the lung, with both areas lined with squamous epithelium. Further, as I said parenthetically above, both exhibit a similar radiation sensitivity--one which I would expect to see enhanced by Erbitux in both settings. One would expect for all of these reasons, I think, to see a similar enhancement to chemotherapy by Erbitux in these similar settings as well--hence my expectation that at least the squamous cell subset of the current NSCLC trials will exhibit a positive response with the addition of Erbitux...I wonder whether any of the oncologists have any thoughts along this same line.
Continued success in your venture, my friend, and I hope that you will continue to drop a note to all of us from time to time!
Best regards,
rjurko (Bob)
Market Data 
Markets 
AI
